Nanoparticles: A Treatment Modality for Lung Cancer

The world has long been plagued by lung cancer with the notion that it is potentially becoming more prevalent over time, alongside smoking being the primary contributory factor. Particularly alarming about this situation is that the early stages are typically asymptomatic, which has always been a barrier for treatment and eventually boosts the mortality rate. It is necessary to avert lung cancer by detecting it in its early stages to lessen the percentage of sufferers needing palliative care. Previously, there had been notable limitations in terms of diagnostic and therapeutic stance, but nanoparticles now turn the tide as the versatility of nanoscale substances makes them reliable in therapeutic studies. Novel theranostic agents based on nanoscale technology are breakthroughs in material science. By utilizing this approach, several targeting strategies, including nanodrug delivery systems, as well as approved and ongoing clinical trials involving nanoformulations for the efficient treatment of lung cancer are thoroughly outlined. Readers will comprehend the research done in this field and currently available therapies by the end of this chapter. Exploring the diversity of nanoparticles in lung cancer as hybrid forms of treatment will shed light on the creation, modification, and application of nanoparticles.